Skip to main content
Premium Trial:

Request an Annual Quote

We've Got One for 'Unwieldy.' Anyone for 'Streamlined and Successful'?

Derek Lowe has a good post about the future of Pfizer now that its merger with Wyeth is complete, basing some of his thoughts on a post from the Wall Street Journal's Health Blog, which interviewed two R&D honchos at the pharma. "Following a popular trend in the industry, Pfizer will continue to decentralize much of its R&D, which will be spread across 18 different units," the WSJ post says.

Lowe thinks the execs could have been more forthcoming, saying that "what might be refreshing is an admission that big mergers - drag-on-for-months am-I-going-to-still-be-here mergers - come with an acute productivity penalty no matter what." He speculates that what Pfizer will look like in a year is "unwieldy."

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.